1. Home
  2. LSF vs XLO Comparison

LSF vs XLO Comparison

Compare LSF & XLO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Laird Superfood Inc.

LSF

Laird Superfood Inc.

HOLD

Current Price

$4.71

Market Cap

48.0M

ML Signal

HOLD

XLO

Xilio Therapeutics Inc.

HOLD

Current Price

$9.17

Market Cap

56.9M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
LSF
XLO
Founded
2015
2016
Country
United States
United States
Employees
N/A
N/A
Industry
Packaged Foods
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Staples
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
48.0M
56.9M
IPO Year
2020
2021

Fundamental Metrics

Financial Performance
Metric
LSF
XLO
Price
$4.71
$9.17
Analyst Decision
Strong Buy
Buy
Analyst Count
1
1
Target Price
$6.00
$28.00
AVG Volume (30 Days)
39.5K
23.3K
Earning Date
05-06-2026
05-14-2026
Dividend Yield
N/A
N/A
EPS Growth
75.28
N/A
EPS
N/A
N/A
Revenue
$49,889,286.00
$43,766,000.00
Revenue This Year
$90.82
N/A
Revenue Next Year
N/A
$168.77
P/E Ratio
$39.82
N/A
Revenue Growth
15.23
589.88
52 Week Low
$1.96
$0.46
52 Week High
$6.50
$9.89

Technical Indicators

Market Signals
Indicator
LSF
XLO
Relative Strength Index (RSI) 62.51 55.69
Support Level $2.23 $7.47
Resistance Level $5.11 $9.22
Average True Range (ATR) 0.41 0.38
MACD 0.06 -0.00
Stochastic Oscillator 89.80 54.04

Price Performance

Historical Comparison
LSF
XLO

About LSF Laird Superfood Inc.

Laird Superfood Inc is engaged in the development and marketing of food and beverage products focused on health and wellness. The company's product portfolio includes coffee creamers, coffee, tea, hot chocolate, hydration and beverage enhancement products, and snacks, made using natural and functional ingredients.

About XLO Xilio Therapeutics Inc.

Xilio Therapeutics Inc is a clinical-stage biotechnology company focused on discovering and developing masked immuno-oncology (I-O) therapies to improve outcomes for people living with cancer. Leveraging its clinically validated masking technology and capabilities, the company develops I-O therapies designed to selectively activate within the tumor microenvironment to achieve durable efficacy without the severe side effects associated with systemically active I-O agents. Its integrated biology and protein engineering approach enables the design and development of potent masked biologics that are activated by tumor-specific proteases.

Share on Social Networks: